Mirion Technologies, Inc.

The stock is still in a corrective regime after a much higher 52-week peak, but it has stabilized well above the low. Trading below the 200-day average and near the middle of its yearly range, the setup is more repair than breakout, with a need to reclaim long-term trend strength.

Street sentiment stays constructive: 8 buys, 1 hold, and no sells. The consensus target sits around $28.25 versus a recent target cluster of $27 to $29, but several firms have trimmed targets in 2026, signaling tempered upside rather than a fresh upgrade wave.

The next report lands after a mixed but mostly positive beat pattern, with 5 beats in the last 7 quarters. Estimates still point higher, with 2026 EPS at $0.538 and 2027 EPS at $0.654, so shareholders should watch whether revenue growth and margin discipline keep pace with the raised bar.

Recent activity is mostly noise from awards, vesting, and in-kind distributions, not a clear discretionary signal. The only open-market style signal in the period is one officer sale of 8,400 shares, while the CEO’s large gift and multiple A/F entries point to compensation-related or administrative flows rather than conviction trading.

Profitability is modest but improving, with a 47.1% gross margin, 1.44% operating margin, and 2.56% net margin. Growth is the stronger story: revenue rose 27.5% year over year, while free cash flow reached $179.7 million, giving the business real operating leverage despite $811.7 million of net debt.

Mirion’s edge is its niche radiation-detection franchise across medical and nuclear safety, where specialized products support recurring compliance and mission-critical use. The stock still trades at a premium-looking 37.16 times earnings, so the valuation depends on sustained growth and margin expansion rather than a cheap multiple.